Clinical research in HIV, HCV coinfection
HIV, HIV/HCV coinfection
Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG: Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin
AIDS Res Hum Retroviruses 32(7): 660-7, Jul 2016.
Hill A, Roberts T, Amorosa V, Pourmand K, Matthews G, Cooke G, Khan H, Cohn J.
: Can HCV antigen testing replace HCV RNA analysis, for monitoring of DAA-based treatment for Hepatitis C? AASLD November 2015 Notes: Poster presentation.
Gowda C, Sheikh U, Maier A, Chang KM, Kaplan DE, Lo Re III V, Amorosa V
: Identifying barriers and potential strategies to improve HCC surveillance for HBV-infected veterans IDSA Oct 2015 Notes: Poster presentation.
Cohn J, Roberts T, Amorosa V, Lemoine M, Hill A: Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment
Curr Opin HIV AIDS 10(5): 369-73, Sep 2015.
Ogdie A, Pang WG, Forde KA, Samir BD, Mulugeta L, Chang KM, Kaplan DE, Amorosa VK, Kostman JR, Reddy RK, Schumacher RH, Lo Re V 3rd: Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection
BMC Musculoskelet Disord 16: 93, April 19 2015.
Gluckman S, Amorosa V, Dummer S, Gordon S: ABIM Update in Infectious Diseases. ABIM Feb 2015.
Gowda C, Compher C, Amorosa VK, Lo Re V 3rd: Association between chronic hepatitis C virus infection and low muscle mass in US adults
J Viral Hepat.
(eds.). 21(12): 938-43, Dec 2014.
Shah NN, Harrison N, Stonecypher M, Frank D, Amorosa V, Svoboda J: Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis
Clin Lymphoma Myeloma Leuk 14(5): e157-60, Oct 2014.
Cho H, Kikuchi M, Li Y, Nakamoto N, Amorosa VK, Valiga ME, Chang KM
: Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection
Front Immunol 5: 265, Jul 8 2014.
Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy
J Viral Hepat
21(4): 288-96, April 2014.
back to top
Last updated: 02/23/2017
The Trustees of the University of Pennsylvania